Pierre Falardeau

Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada.

Verlyx Pharma, Inc. develops cancer treatments. It is a pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. The firm’s product VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. The company was founded in 1999 by Terry Chow and David Griller and is headquartered in Montréal, Canada.

Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology

FOLIA BIOTECH, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on exploiting its proprietary immuno-therapeutic platform to bring to market efficacious therapeutic products that fulfill large unmet needs principally in oncology and certain infectious diseases. The company was founded by Denis Leclerc in 2006 and is headquartered in Quebec, Canada.

EVAH Corp. develops animal health technologies. The Canadian company was founded in 2020 by Michel Fortin and Nicole Blanchard. Michel Fortin has been the CEO since 2020.